Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Expected to Rise, Oppenheimer Analyst Says

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price target upped by stock analysts at Oppenheimer from $63.00 to $65.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s price objective indicates a potential upside of 44.99% from the stock’s previous close.

Separately, William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $54.20.

Tarsus Pharmaceuticals Stock Performance

TARS opened at $44.83 on Thursday. The stock’s 50 day moving average price is $37.84 and its two-hundred day moving average price is $32.52. The firm has a market capitalization of $1.71 billion, a P/E ratio of -11.77 and a beta of 1.00. The company has a quick ratio of 6.99, a current ratio of 7.03 and a debt-to-equity ratio of 0.28. Tarsus Pharmaceuticals has a 12-month low of $15.60 and a 12-month high of $52.99.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Swiss National Bank grew its stake in Tarsus Pharmaceuticals by 1.4% during the first quarter. Swiss National Bank now owns 42,433 shares of the company’s stock worth $1,542,000 after buying an additional 600 shares during the last quarter. Sei Investments Co. boosted its stake in Tarsus Pharmaceuticals by 128.2% in the first quarter. Sei Investments Co. now owns 32,804 shares of the company’s stock worth $1,192,000 after purchasing an additional 18,426 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Tarsus Pharmaceuticals by 38,907.8% during the first quarter. Russell Investments Group Ltd. now owns 30,036 shares of the company’s stock worth $1,092,000 after purchasing an additional 29,959 shares during the last quarter. ProShare Advisors LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the first quarter valued at $277,000. Finally, Bleakley Financial Group LLC bought a new position in shares of Tarsus Pharmaceuticals in the first quarter valued at about $223,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.